Clinical Trial: NCT04956640
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-05-29 |
Study Overview
Brief Summary
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Official Title
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Intervention / Treatment
- Drug: LY3537982
- Drug: Pembrolizumab
- Drug: Cetuximab
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
Other Study ID Numbers
- LOXO-RAS-20001
- 2021-000595-12
- J3M-OX-JZQA
- MK-3475-E27/KEYNOTE E27
- 2022-502756-31-00
Start Date (Actual)
2021-07-19
Primary Completion Date (Estimated)
2027-04
Study Completion Date (Estimated)
2027-04
Enrollment (Estimated)
540
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-05-29 |
Study Overview
Brief Summary
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Official Title
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
Intervention / Treatment
- Drug: LY3537982
- Drug: Pembrolizumab
- Drug: Cetuximab
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
Other Study ID Numbers
- LOXO-RAS-20001
- 2021-000595-12
- J3M-OX-JZQA
- MK-3475-E27/KEYNOTE E27
- 2022-502756-31-00
Start Date (Actual)
2021-07-19
Primary Completion Date (Estimated)
2027-04
Study Completion Date (Estimated)
2027-04
Enrollment (Estimated)
540
Study Type
Interventional
Phase
Phase 1, Phase 2